NYU Langone Health is embedding OpenEvidence's AI-powered clinical evidence platform directly into the Epic EHR across its hospitals, ambulatory network, Family Health Centers, and NYU medical training sites.

The collaboration aims to support the system’s roughly 12.4 million outpatient visits annually by providing Patient Aware Clinical Intelligence inside Epic for clinicians in New York City, Long Island, and beyond.

Usage metrics show growth: monthly active users rose from 355 in January 2024 to 703,265 by June 2026, with queries per active user increasing from 18 to 39.5 per month and 2026 maintaining about 90% month-to-month retention.

A JAMA study covering January 2024 through June 2026 notes nearly 1 million U.S. clinicians used OpenEvidence to submit 271 million AI-enabled clinical queries across a wide range of specialties.

Clinicians will be able to ask complex natural-language clinical questions within the EHR and receive literature-grounded answers without leaving the Epic workflow.

The system links patient context to peer-reviewed medical literature, delivering evidence directly into each patient’s chart to support bedside decision-making.

NYU Langone’s scale includes more than 12 million outpatient visits annually, 421,000 emergency department visits, multiple inpatient locations, and over 400 outpatient sites, with a staff of 6,000+ physicians and 54,000+ employees.

Systemwide details note 12.4 million outpatient visits and 421,000 annual ED visits, seven inpatient locations, 400+ outpatient sites across the region and Florida, and a substantial clinical workforce and trainee presence.

NYU Langone executive Nader Mherabi underscored safety and scale in adopting OpenEvidence, while OpenEvidence founder/CEO Daniel Nadler said the world medical literature is now in the room for all twelve million visits.

Daniel Nadler emphasizes that placing OpenEvidence inside NYU Langone’s chart makes the world’s medical literature readily accessible during about 12 million yearly visits.

The NYU Langone collaboration is part of a broader 2026 OpenEvidence rollout, including partnerships with Memorial Sloan Kettering Cancer Center, University of Texas Medical Branch, and AdventHealth to embed literature- and guideline-based decision support at the point of care.

Context: MSK focuses on oncology knowledge bases; UTMB went live in March 2026 with broad clinician use; AdventHealth’s rollout across multiple clinical roles occurred in October 2026.